As part of a global discovery collaboration, Sanofi has gained access to Selecta Biosciences’ SVP™ (Synthetic Vaccine Particle) platform to develop a targeted, antigen-specific immunotherapy for a life-threatening food allergy; it also has an option to develop two additional immunotherapies each to a specific food or aeroallergen. The deal represents Selecta’s first big pharma alliance and could be worth as much as US$900 M to the company if three immunotherapy candidates are successfully commercialised.